TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Open-Label, Comparative Bridging Study of CAELYX® Versus Topotecan HCl in Subjects With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Brief Summary: The purpose of this study is to compare the effectiveness between CAELYX and topotecan hydrochloride (HCl) in Chinese participants with recurrent epithelial ovarian carcinoma following failure of first-line, platinum-based chemotherapy, who have received no more than one prior platinum-based regimen therapy.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vandetanib | Intervention Type: DRUG; Name: Vandetanib; Assigned to Arm(s): 1
B: Arm Label: Olaparib and Cediranib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Cediranib | Arm Label: Olaparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olaparib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib, Olaparib and Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Olaparib and Cediranib
C: Arm Label: BIBF 1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120, Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): BIBF 1120 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): BIBF 1120 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): BIBF 1120
D: Arm Label: CAELYX; Type: EXPERIMENTAL; Interventions: Drug: CAELYX | Arm Label: Topotecan hydrochloride (HCl); Type: ACTIVE_COMPARATOR; Interventions: Drug: Topotecan HCl | Intervention Type: DRUG; Name: CAELYX; Assigned to Arm(s): CAELYX | Intervention Type: DRUG; Name: Topotecan HCl; Assigned to Arm(s): Topotecan hydrochloride (HCl)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Live Birth After Fresh Embryo Transfer vs Elective Embryo Cryopreservation/Frozen Embryo Transfer in Women With Polycystic Ovary Syndrome Undergoing IVF: A Multi-center Prospective Randomized Clinical Trial
Brief Summary: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of childbearing age. However, the optimal infertility treatment for PCOS patients is still a matter of controversy. Despite producing more follicles and more oocytes than other women undergoing controlled ovarian hyperstimulation during an IVF cycle, women with PCOS have comparable or lower pregnancy rates. Additionally women with PCOS patients undergoing IVF have a higher risk of developing ovarian hyperstimulation syndrome (OHSS), which may be aggravated by pregnancy after an embryo transfer in a fresh cycle. Further women with PCOS are thought to have higher rates of later pregnancy complications including spontaneous abortion, pre-eclampsia, and preterm labor that may be related to impaired implantation in the superovulated endometrium. We propose a randomized clinical trial of elective embryo cryopreservation followed by a programmed cycle of endometrial preparation and frozen embryo transfer (FET) compared to fresh embryo transfer in women with PCOS undergoing in vitro fertilization (IVF).


Options:
A: Arm Label: fresh embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: fresh embryo transfer | Arm Label: frozen-thawed embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: frozen-thawed embryo transfer | Intervention Type: OTHER; Name: fresh embryo transfer; Assigned to Arm(s): fresh embryo transfer group | Intervention Type: OTHER; Name: frozen-thawed embryo transfer; Assigned to Arm(s): frozen-thawed embryo transfer group
B: Arm Label: Freeze-all protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Freeze-all protocol | Arm Label: Fresh transfer protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fresh transfer protocol | Intervention Type: PROCEDURE; Name: Freeze-all protocol; Assigned to Arm(s): Freeze-all protocol | Intervention Type: PROCEDURE; Name: Fresh transfer protocol; Assigned to Arm(s): Fresh transfer protocol
C: Arm Label: Provera; Type: EXPERIMENTAL; Interventions: Drug: Provera 10 mg. | Arm Label: Orgalutrán Ganirelix (GnRH antagonist); Type: ACTIVE_COMPARATOR; Interventions: Drug: Ganirelix (GnRH antagonist) | Intervention Type: DRUG; Name: Provera 10 mg.; Assigned to Arm(s): Provera | Intervention Type: DRUG; Name: Ganirelix (GnRH antagonist); Assigned to Arm(s): Orgalutrán Ganirelix (GnRH antagonist)
D: Arm Label: Progevera; Type: EXPERIMENTAL; Interventions: Drug: Progevera | Arm Label: Orgalutran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Orgalutran | Intervention Type: DRUG; Name: Progevera; Assigned to Arm(s): Progevera | Intervention Type: DRUG; Name: Orgalutran; Assigned to Arm(s): Orgalutran

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Livslots Angered - A Randomized Controlled Trial of a Community-based Health-promoting and Disease-preventive Program for Older Foreign Born Adults
Brief Summary: The overarching aim with this study was to develop, implement and evaluate a health promoting programme for people from Finland or the Western Balkan region, who were 70 years of age or older and independent daily activites (1). The aim of the programme was to prevent or delay dependence in daily activities, health decline, and frailty. The study focused on both evaluation and implementation and the data collection finished in 2016


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard hemodialysis dietary instruction | Arm Label: B; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral counseling plus PDA-based self-monitoring of diet | Intervention Type: BEHAVIORAL; Name: Standard hemodialysis dietary instruction; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Behavioral counseling plus PDA-based self-monitoring of diet; Assigned to Arm(s): B
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Care for Korean Americans | Intervention Type: BEHAVIORAL; Name: Diabetes Care for Korean Americans; Assigned to Arm(s): 1
C: Arm Label: Senior meetings; Type: EXPERIMENTAL; Interventions: Behavioral: Senior meetings | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Senior meetings; Assigned to Arm(s): Senior meetings
D: Arm Label: Walking Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Intervention | Arm Label: Wait-list control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Walking Intervention; Assigned to Arm(s): Walking Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Giving Omega-3 Fatty Acids to Elderly Patients Diagnosed With Acute Myocardial Infarction to Investigate the Effect on Cardiovascular Morbidity and Mortality
Brief Summary: The aim of the present study is to investigate the possible effects of supplementation with 1.8 g/day of n-3 polyunsaturated fatty acids on cardiovascular morbidity and mortality during a follow-up period of 2 years in an elderly population after having experienced an acute myocardial infarction.

The hypothesis is that this supplementation on top of modern therapy will reduce the combined cardiovascular end-point of death, non-fatal myocardial infarction, stroke, revascularizations or hospitalization for new or worsened heart failure with at least 30%.


Options:
A: Arm Label: Omega 3 recipient arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega 3 Fish Oil supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega 3 Fish Oil supplements; Assigned to Arm(s): Omega 3 recipient arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Pikasol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pikasol | Arm Label: Corn oil; Type: PLACEBO_COMPARATOR; Interventions: Other: Corn oil | Intervention Type: DRUG; Name: Pikasol; Assigned to Arm(s): Pikasol | Intervention Type: OTHER; Name: Corn oil; Assigned to Arm(s): Corn oil
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega 3 (n-3 PUFA) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega 3 (n-3 PUFA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Fish oil; Type: EXPERIMENTAL; Interventions: Drug: Fish oil | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Fish oil; Assigned to Arm(s): Fish oil

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Giving Omega-3 Fatty Acids to Elderly Patients Diagnosed With Acute Myocardial Infarction to Investigate the Effect on Cardiovascular Morbidity and Mortality
Brief Summary: The aim of the present study is to investigate the possible effects of supplementation with 1.8 g/day of n-3 polyunsaturated fatty acids on cardiovascular morbidity and mortality during a follow-up period of 2 years in an elderly population after having experienced an acute myocardial infarction.

The hypothesis is that this supplementation on top of modern therapy will reduce the combined cardiovascular end-point of death, non-fatal myocardial infarction, stroke, revascularizations or hospitalization for new or worsened heart failure with at least 30%.


Options:
A: Intervention Type: PROCEDURE; Name: Supplementation with fish oil versus placebo; Assigned to Arm(s): N/A
B: Arm Label: Vitamin D + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D3, Drug: omega-3 fatty acids (fish oil) | Arm Label: Vitamin D + fish oil placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D3, Dietary Supplement: Fish oil placebo | Arm Label: Vitamin D placebo + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Drug: omega-3 fatty acids (fish oil), Dietary Supplement: Vitamin D3 placebo | Arm Label: Vitamin D placebo + fish oil placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 placebo, Dietary Supplement: Fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D3; Assigned to Arm(s): Vitamin D + fish oil, Vitamin D + fish oil placebo | Intervention Type: DRUG; Name: omega-3 fatty acids (fish oil); Assigned to Arm(s): Vitamin D + fish oil, Vitamin D placebo + fish oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 placebo; Assigned to Arm(s): Vitamin D placebo + fish oil, Vitamin D placebo + fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish oil placebo; Assigned to Arm(s): Vitamin D + fish oil placebo, Vitamin D placebo + fish oil placebo
C: Arm Label: Pikasol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pikasol | Arm Label: Corn oil; Type: PLACEBO_COMPARATOR; Interventions: Other: Corn oil | Intervention Type: DRUG; Name: Pikasol; Assigned to Arm(s): Pikasol | Intervention Type: OTHER; Name: Corn oil; Assigned to Arm(s): Corn oil
D: Arm Label: Safflower oil; Type: EXPERIMENTAL; Interventions: Other: Safflower oil | Arm Label: Control group (no diet instruction); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Safflower oil; Assigned to Arm(s): Safflower oil

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Giving Omega-3 Fatty Acids to Elderly Patients Diagnosed With Acute Myocardial Infarction to Investigate the Effect on Cardiovascular Morbidity and Mortality
Brief Summary: The aim of the present study is to investigate the possible effects of supplementation with 1.8 g/day of n-3 polyunsaturated fatty acids on cardiovascular morbidity and mortality during a follow-up period of 2 years in an elderly population after having experienced an acute myocardial infarction.

The hypothesis is that this supplementation on top of modern therapy will reduce the combined cardiovascular end-point of death, non-fatal myocardial infarction, stroke, revascularizations or hospitalization for new or worsened heart failure with at least 30%.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zodin (drug) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olive oil (placebo) | Intervention Type: DRUG; Name: Zodin (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Olive oil (placebo); Assigned to Arm(s): 2
B: Arm Label: Pikasol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pikasol | Arm Label: Corn oil; Type: PLACEBO_COMPARATOR; Interventions: Other: Corn oil | Intervention Type: DRUG; Name: Pikasol; Assigned to Arm(s): Pikasol | Intervention Type: OTHER; Name: Corn oil; Assigned to Arm(s): Corn oil
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega 3 (n-3 PUFA) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega 3 (n-3 PUFA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Lower fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Lower carbohydrate diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Walnut-rich diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Intervention Type: BEHAVIORAL; Name: Weight loss; Assigned to Arm(s): Lower carbohydrate diet, Lower fat diet, Walnut-rich diet

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Giving Omega-3 Fatty Acids to Elderly Patients Diagnosed With Acute Myocardial Infarction to Investigate the Effect on Cardiovascular Morbidity and Mortality
Brief Summary: The aim of the present study is to investigate the possible effects of supplementation with 1.8 g/day of n-3 polyunsaturated fatty acids on cardiovascular morbidity and mortality during a follow-up period of 2 years in an elderly population after having experienced an acute myocardial infarction.

The hypothesis is that this supplementation on top of modern therapy will reduce the combined cardiovascular end-point of death, non-fatal myocardial infarction, stroke, revascularizations or hospitalization for new or worsened heart failure with at least 30%.


Options:
A: Intervention Type: BEHAVIORAL; Name: Dietary intake; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle factors; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Blood biomarkers; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Health; Assigned to Arm(s): N/A | Intervention Type: GENETIC; Name: DNA; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Mental well-being; Assigned to Arm(s): N/A
B: Arm Label: Luxembourg diet + wine; Type: OTHER; Interventions: Dietary Supplement: Luxembourg variant of Mediterranean diet + physical activity +/- wine | Arm Label: conventional + wine; Type: OTHER; Interventions: Dietary Supplement: Conventional diet +/- wine | Arm Label: conventional; Type: OTHER; Interventions: Dietary Supplement: Conventional diet +/- wine | Arm Label: Luxembourg diet; Type: OTHER; Interventions: Dietary Supplement: Luxembourg variant of Mediterranean diet + physical activity +/- wine | Intervention Type: DIETARY_SUPPLEMENT; Name: Conventional diet +/- wine; Assigned to Arm(s): conventional, conventional + wine | Intervention Type: DIETARY_SUPPLEMENT; Name: Luxembourg variant of Mediterranean diet + physical activity +/- wine; Assigned to Arm(s): Luxembourg diet, Luxembourg diet + wine
C: Arm Label: Pikasol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pikasol | Arm Label: Corn oil; Type: PLACEBO_COMPARATOR; Interventions: Other: Corn oil | Intervention Type: DRUG; Name: Pikasol; Assigned to Arm(s): Pikasol | Intervention Type: OTHER; Name: Corn oil; Assigned to Arm(s): Corn oil
D: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Giving Omega-3 Fatty Acids to Elderly Patients Diagnosed With Acute Myocardial Infarction to Investigate the Effect on Cardiovascular Morbidity and Mortality
Brief Summary: The aim of the present study is to investigate the possible effects of supplementation with 1.8 g/day of n-3 polyunsaturated fatty acids on cardiovascular morbidity and mortality during a follow-up period of 2 years in an elderly population after having experienced an acute myocardial infarction.

The hypothesis is that this supplementation on top of modern therapy will reduce the combined cardiovascular end-point of death, non-fatal myocardial infarction, stroke, revascularizations or hospitalization for new or worsened heart failure with at least 30%.


Options:
A: Arm Label: Vitamin D + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D3, Drug: omega-3 fatty acids (fish oil) | Arm Label: Vitamin D + fish oil placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D3, Dietary Supplement: Fish oil placebo | Arm Label: Vitamin D placebo + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Drug: omega-3 fatty acids (fish oil), Dietary Supplement: Vitamin D3 placebo | Arm Label: Vitamin D placebo + fish oil placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 placebo, Dietary Supplement: Fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D3; Assigned to Arm(s): Vitamin D + fish oil, Vitamin D + fish oil placebo | Intervention Type: DRUG; Name: omega-3 fatty acids (fish oil); Assigned to Arm(s): Vitamin D + fish oil, Vitamin D placebo + fish oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 placebo; Assigned to Arm(s): Vitamin D placebo + fish oil, Vitamin D placebo + fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish oil placebo; Assigned to Arm(s): Vitamin D + fish oil placebo, Vitamin D placebo + fish oil placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zodin (drug) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olive oil (placebo) | Intervention Type: DRUG; Name: Zodin (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Olive oil (placebo); Assigned to Arm(s): 2
C: Arm Label: Pikasol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pikasol | Arm Label: Corn oil; Type: PLACEBO_COMPARATOR; Interventions: Other: Corn oil | Intervention Type: DRUG; Name: Pikasol; Assigned to Arm(s): Pikasol | Intervention Type: OTHER; Name: Corn oil; Assigned to Arm(s): Corn oil
D: Intervention Type: DRUG; Name: Epanova™ (Omega-3 Free Fatty Acids); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Giving Omega-3 Fatty Acids to Elderly Patients Diagnosed With Acute Myocardial Infarction to Investigate the Effect on Cardiovascular Morbidity and Mortality
Brief Summary: The aim of the present study is to investigate the possible effects of supplementation with 1.8 g/day of n-3 polyunsaturated fatty acids on cardiovascular morbidity and mortality during a follow-up period of 2 years in an elderly population after having experienced an acute myocardial infarction.

The hypothesis is that this supplementation on top of modern therapy will reduce the combined cardiovascular end-point of death, non-fatal myocardial infarction, stroke, revascularizations or hospitalization for new or worsened heart failure with at least 30%.


Options:
A: Arm Label: N-3 PUFA; Type: EXPERIMENTAL; Interventions: Drug: N-3 Polyunsaturated Fatty Acids | Arm Label: Olive oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo: Olive oil | Intervention Type: DRUG; Name: N-3 Polyunsaturated Fatty Acids; Assigned to Arm(s): N-3 PUFA | Intervention Type: DRUG; Name: Placebo: Olive oil; Assigned to Arm(s): Olive oil
B: Arm Label: Pikasol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pikasol | Arm Label: Corn oil; Type: PLACEBO_COMPARATOR; Interventions: Other: Corn oil | Intervention Type: DRUG; Name: Pikasol; Assigned to Arm(s): Pikasol | Intervention Type: OTHER; Name: Corn oil; Assigned to Arm(s): Corn oil
C: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure
D: Arm Label: AMR101; Type: EXPERIMENTAL; Interventions: Drug: AMR101, Drug: Statin therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Statin therapy | Intervention Type: DRUG; Name: AMR101; Assigned to Arm(s): AMR101 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Statin therapy; Assigned to Arm(s): AMR101, Placebo

Answer: B